CytomX Therapeutics, Inc. (CTMX) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$2.86

From 52W high−59.11%

Volume9.60M

Market cap$601.40M

P/E (TTM)—

P/S (TTM)32.9x

Div yield—

Key dataSep 18, 2026

Open

$2.86

From 52W high

−59.11%

Volume

9.60M

Market cap

$601.40M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−3.5x

P/E (TTM)

—

RSI (14)

32.9

MomentumView details →

1D Return

−2.13%

YTD Return

−35.33%

SummaryUpdated Jun 1, 2026

CytomX Therapeutics, Inc. (NASDAQ:CTMX) is an oncology-focused biopharmaceutical company founded in 2008 and headquartered in South San Francisco, California. The company went public in October 2015 and has developed a proprietary technology platform called Probody therapeutics for creating conditionally activated cancer treatments. CytomX operates primarily as a research and development organization, advancing both internal drug candidates and partnered programs with major pharmaceutical companies including Bristol-Myers Squibb, Amgen, Astellas, and others.

Ask drillr about CytomX Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−3.5x

EV/Sales

15.1x

P/S (TTM)

32.9x

P/B (TTM)

2.0x

ProfitabilityView details →

Gross Margin

98.63%

Net Margin

−435.21%

EBITDA Margin

−427.43%

ROE (TTM)

−26.37%

ROA (TTM)

−20.89%

Asset Turnover

0.05x

GrowthView details →

Revenue YoY

−87.03%

EPS YoY

—

FCF YoY

−6.18%

Revenue CAGR 3Y

+12.75%

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

−2.13%

YTD Return

−35.33%

1Y Return

+39.14%

RSI (14)

32.9

vs 50D SMA

−18.25%

vs 200D SMA

−33.09%

Capital & dividendView details →

Debt/Equity

0.02x

Current Ratio

9.36x

Quick Ratio

9.36x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.09

EPS Surprise

−16.76%

Beats (12Q)

5/12

Next Q EPS Est

−$0.07

Avg Surprise (4Q)

−62.22%

Rev Surprise

−88.55%

Financials snapshotView financials →

Revenue (TTM)

18.30M

Net Income (TTM)

−79.65M

Op. CF (TTM)

−82.41M

Next earningsNov 5, 2026 →

Latest newsMore news →

CytomX Therapeutics reported a Q2 2026 loss of $0.09 per share, beating the Zacks Consensus Estimate of a loss of $0.11, compared to break-even earnings per share a year ago.45d ago

CytomX Therapeutics appointed Charles Fuchs, M.D., M.P.H. as a Class II director, effective July 24, 2026.56d ago

Similar companies

CorMedix Inc.CRMD Shattuck Labs, Inc.STTK AgomAb Therapeutics N.V. American Depositary SharesAGMB Bright Minds Biosciences Inc.DRUG Phathom Pharmaceuticals, Inc.PHAT 3D Medicines Inc.01244.HK Find similar companies →

Latest newsMore news →

CytomX Therapeutics reported a Q2 2026 loss of $0.09 per share, beating the Zacks Consensus Estimate of a loss of $0.11, compared to break-even earnings per share a year ago.45d ago CytomX Therapeutics appointed Charles Fuchs, M.D., M.P.H. as a Class II director, effective July 24, 2026.56d ago